- Home
- Publications
- Publication Search
- Publication Details
Title
Are MPNs Vascular Diseases?
Authors
Keywords
Myeloproliferative neoplasms, Thrombosis, Risk factors, Therapy, Hematologic malignancy
Journal
Current Hematologic Malignancy Reports
Volume 8, Issue 4, Pages 307-316
Publisher
Springer Nature
Online
2013-09-14
DOI
10.1007/s11899-013-0176-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
- (2013) H. Gisslinger et al. BLOOD
- Mechanisms of thrombosis in cancer
- (2013) Anna Falanga et al. THROMBOSIS RESEARCH
- Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
- (2013) Richard T Silver et al. Expert Review of Hematology
- JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway
- (2012) M. De Grandis et al. BLOOD
- Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis
- (2012) J. H. Smalberg et al. BLOOD
- Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
- (2012) S. Pascale et al. BLOOD
- Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation
- (2012) V. Rosti et al. BLOOD
- JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth
- (2012) Lori N. Griner et al. BRITISH JOURNAL OF HAEMATOLOGY
- Antithrombotic Therapy for VTE Disease
- (2012) Clive Kearon et al. CHEST
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies
- (2012) Ilze Dienava-Verdoold et al. THROMBOSIS AND HAEMOSTASIS
- Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera
- (2011) Marina Panova-Noeva et al. AMERICAN JOURNAL OF HEMATOLOGY
- Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146+ immunomagnetic enrichment-flow cytometry and soluble E-selectin detection
- (2011) Angelo Belotti et al. AMERICAN JOURNAL OF HEMATOLOGY
- Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study
- (2011) Francesca Palandri et al. ANNALS OF HEMATOLOGY
- Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia
- (2011) N. Maugeri et al. BLOOD
- Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
- (2011) A. Carobbio et al. BLOOD
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
- (2011) Magnus Björkholm et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Atherosclerosis: current pathogenesis and therapeutic options
- (2011) Christian Weber et al. NATURE MEDICINE
- In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband
- (2011) Elena Rossi et al. THROMBOSIS AND HAEMOSTASIS
- Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms
- (2011) N. C. P. Cross Hematology-American Society of Hematology Education Program
- Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
- (2010) A. Alvarez-Larran et al. BLOOD
- Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
- (2010) T. Barbui et al. HAEMATOLOGICA
- Myeloproliferative Disorders and the Hyperviscosity Syndrome
- (2010) Bruce D. Adams et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin
- (2010) B. K. MAHMOODI et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy andJAK2–V617Fmutational status
- (2010) Jacek Treliński et al. LEUKEMIA & LYMPHOMA
- Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms
- (2010) Giuseppe Cella et al. THROMBOSIS AND HAEMOSTASIS
- Rare thromboses of cerebral, splanchnic and upper-extremity veins
- (2010) Valerio De Stefano et al. THROMBOSIS AND HAEMOSTASIS
- Thrombosis in primary myelofibrosis: incidence and risk factors
- (2009) T. Barbui et al. BLOOD
- The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome
- (2009) S. Sozer et al. BLOOD
- Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia
- (2009) V. De Stefano et al. HAEMATOLOGICA
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia
- (2009) F. PASSAMONTI et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- The role of procoagulants and anticoagulants in the development of venous thromboembolism
- (2009) Rogier M. Bertina THROMBOSIS RESEARCH
- Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review
- (2009) Federico Lussana et al. THROMBOSIS RESEARCH
- Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence andJAK2 V617F allele burden
- (2008) Eduardo Arellano-Rodrigo et al. AMERICAN JOURNAL OF HEMATOLOGY
- Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera
- (2008) M. Marchetti et al. BLOOD
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
- The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases
- (2008) J.-J. Kiladjian et al. BLOOD
- Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
- (2008) V. De Stefano et al. HAEMATOLOGICA
- Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases
- (2008) A Alonci et al. HEMATOLOGICAL ONCOLOGY
- Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia
- (2008) Alessandra Carobbio et al. JOURNAL OF CLINICAL ONCOLOGY
- Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation
- (2008) R Landolfi et al. LEUKEMIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now